[Fluvastatin induces apoptosis on human tongue carcinoma cell line HSC-3]

Kimiko Fujiwara1, Masanobu Tsubaki, Yuzuru Yamazoe

  • 1Department of Pharmacy, Kinki University Hospital, Osakasayama City, Japan.

Insights

Fluvastatin, a statin drug, induces cancer cell death (apoptosis) in tongue carcinoma by blocking essential cell survival signals. This mechanism suggests fluvastatin

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and suppress cancer cell proliferation.
  • The anti-cancer effects of statins on head and neck carcinoma remain largely uninvestigated.

Purpose of the Study:

  • To elucidate the mechanism by which fluvastatin induces apoptosis in human tongue squamous cell carcinoma (HSC-3) cells.
  • To explore the potential of fluvastatin as an anti-cancer therapeutic for tongue carcinoma.

Main Methods:

  • Investigated fluvastatin's effect on caspase-3 activity and apoptosis induction in HSC-3 cells.
  • Assessed the impact of geranylgeranyl pyrophosphate (GGPP) supplementation on fluvastatin-induced apoptosis.
  • Analyzed the phosphorylation status of extracellular signal-regulated kinase (ERK) 1/2 following fluvastatin treatment.
  • Utilized U0126, a MEK1/2 inhibitor, to further investigate the role of the ERK pathway.

Main Results:

  • Fluvastatin significantly increased caspase-3 activity, indicating apoptosis induction.
  • The addition of GGPP reversed the apoptotic effects of fluvastatin.
  • Fluvastatin treatment led to a marked decrease in phosphorylated ERK1/2 levels.
  • U0126, a MEK1/2 inhibitor, also induced apoptosis in HSC-3 cells.

Conclusions:

  • Fluvastatin induces apoptosis in tongue carcinoma cells by inhibiting GGPP biosynthesis, which subsequently reduces phosphorylated ERK1/2 levels.
  • These findings suggest that fluvastatin holds promise as a potential anti-cancer agent for tongue carcinoma.